Femoral fixture for a hip joint prosthesis
Latest AstraZeneca AB Patents:
- IRAK4 inhibitors
- Pharmaceutical composition
- Methods of treating chronic kidney disease with dapagliflozin
- Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
- Arginase inhibitors and methods of use thereof
Description
FIG. 1 is a top perspective view of a femoral fixture for a hip joint prosthesis showing our new design;
FIG. 2 is a bottom perspective view thereof;
FIG. 3 is a side elevational view thereof;
FIG. 4 is a top plan view thereof; and,
FIG. 5 is a bottom plan view thereof.
Claims
The ornamental design for a femoral fixture for a hip joint prosthesis, as shown and described.
Referenced Cited
U.S. Patent Documents
Foreign Patent Documents
Other references
| 5980575 | November 9, 1999 | Albrektsson et al. |
| 9725939 | July 1997 | WO |
- U.S. application No. 08/776,987, Albrektsson et al., filed Feb. 18, 1997.
Patent History
Patent number: D455212
Type: Grant
Filed: Apr 4, 2001
Date of Patent: Apr 2, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Thomas Albrektsson (Molndal), Magnus Jacobsson (Gothenburg), Stig Wennberg (Gunnilse), Lars Carlsson (Kullavik), Warren Macdonald (Boscombe)
Primary Examiner: Antoine Duval Davis
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,717
Type: Grant
Filed: Apr 4, 2001
Date of Patent: Apr 2, 2002
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Thomas Albrektsson (Molndal), Magnus Jacobsson (Gothenburg), Stig Wennberg (Gunnilse), Lars Carlsson (Kullavik), Warren Macdonald (Boscombe)
Primary Examiner: Antoine Duval Davis
Attorney, Agent or Law Firm: White & Case LLP
Application Number: 29/139,717
Classifications
